FAMMM syndrome and pancreatic cancer — what a CDKN2A change actually means

Most people reading this arrived by one of two routes. Either a dermatologist looked at a lot of unusual moles and mentioned a syndrome with a long name, or a relative had a genetic test and the word CDKN2A appeared in the report. Searches for FAMMM syndrome pancreatic cancer almost always begin in one of those two places, and the question underneath them is the same: does this mean the pancreas is next?

The honest answer is no for most people, and yes it changes what should happen. FAMMM stands for familial atypical multiple mole melanoma. It describes families in which melanoma appears in more than one close blood relative, often younger than usual, alongside a large number of moles a dermatologist would call atypical. In many of those families — not all — the underlying cause is an inherited change in a gene called CDKN2A, which normally helps hold cell division in check. A smaller number of families carry a change in a related gene, CDK4.

The reason an oncology service writes about a skin condition is that the same inherited change also raises the risk of pancreatic ductal adenocarcinoma. That is why the condition is sometimes described as a melanoma pancreatic cancer syndrome, and why CDKN2A pancreatic cancer risk is discussed in guidance that otherwise has nothing to do with skin. It sits alongside BRCA2, PALB2 and Lynch syndrome in the small group of inherited conditions that genuinely change how the pancreas is watched.

Two things are worth saying plainly before any detail. Having many moles does not mean you have FAMMM — atypical moles are common, and most people who have them carry no inherited syndrome at all. And carrying a CDKN2A change does not mean you will develop pancreatic cancer; most carriers never do. What it does mean is that you belong to one of the few groups for whom this disease can realistically be looked for early. The wider inherited picture is set out in is pancreatic cancer hereditary?, and the disease itself — symptoms, tests and staging — in our complete guide to pancreatic cancer.

• Melanoma in two or more close blood relatives on the same side of the family. This is the pattern that most often leads to CDKN2A testing being offered at all.
• More than one separate melanoma in the same person, particularly where the first appeared younger than usual.
• Melanoma and pancreatic cancer in the same family line. That combination is the classic reason this syndrome gets raised, and the reason an oncologist becomes involved at all.
• A large number of atypical moles alongside any melanoma in the family — the moles matter as part of a pattern, never on their own.
• A CDKN2A change already confirmed in a relative. Testing then becomes simple, specific and quick, and is offered to the rest of the family.
• Pancreatic cancer in a close relative, with melanoma anywhere in the family — see is pancreatic cancer hereditary? for how family patterns are read.
• You are carrying a worry you cannot put down. Mapping a family tree properly is a legitimate reason to book, and more often than not it ends the worry rather than confirming it.

1. 1

   A free 45-minute consultation, not a five-minute triage

   We take the family history properly — every melanoma and every pancreatic cancer, on both sides, and how old each relative was at diagnosis. A risk assessment is built from those specifics, never from a mole count.

   In-house at CION
2. 2

   Genetic counselling before any test

   You find out in advance what a positive, a negative and an uncertain result would each mean — for you, for your children and for your brothers and sisters — before a sample is taken. Counselling is delivered by CION.

   In-house at CION
3. 3

   Germline testing, where the pattern warrants it

   Testing looks at CDKN2A alongside the other genes that matter for pancreatic and melanoma risk. A result that changes nothing is a common outcome and a genuinely useful one — it releases a whole family from years of wondering.

   In-house at CION
4. 4

   A surveillance plan, if you do carry the change

   Pancreatic surveillance for carriers is imaging at intervals, not a blood test. MRI with MRCP and pancreatic-protocol CT are ordered and reported by CION. Endoscopic ultrasound, where it is used alongside the MRI, is arranged with specialist gastroenterology and endoscopy partner centres and may be billed there. Skin surveillance runs in parallel with a dermatologist.

   In-house at CION · endoscopy coordinated
5. 5

   If anything is ever found, the pathway is already built

   Chemotherapy, radiation, chemoradiation and SBRT are delivered by CION. All pancreatic surgery, staging laparoscopy, ERCP and stenting, coeliac plexus block and PET-CT are coordinated with specialist hepatobiliary, gastroenterology and endoscopy partner centres and may be billed there. The whole route is set out in pancreatic cancer treatment in Hyderabad.

   Coordinated with specialist partner centres

A positive result changes nothing about your health on the day it arrives. You are exactly as well as you were the day before. What changes is the plan — and for a cancer usually found late and by accident, being one of the few people who can be watched deliberately is not a small thing. Most people describe the first few weeks as unsettling and the months after that as steadier, once the schedule is set and somebody else is holding it.

The result also belongs to your family, and that is the part people find hardest. Once a change is confirmed in one person, relatives can be offered a single, specific test for that exact change rather than a full panel. Relatives who test negative for the family change are usually released from extra surveillance altogether, which is frequently the most valuable outcome of the whole exercise. Testing children is generally deferred until adulthood, because nothing about their care would change before then. Those conversations are what genetic counselling is for, and they are better had slowly.

Do not let the pancreas crowd out the skin. In this syndrome melanoma is the more likely problem, and it is the one where early detection is most reliable — regular checks with a dermatologist, sensible sun protection, and getting anything new or changing looked at rather than photographed and forgotten. How skin cancers are assessed and treated is covered on our skin cancer hub.

Be honest with yourself about what surveillance can and cannot do. It improves the chance of finding something at a stage where treatment works, and it cannot promise that. It also throws up occasional uncertain findings that need repeating rather than acting on, and that is part of the deal rather than a failure of the programme. If the waiting around scans becomes hard to carry, our psycho-oncology and supportive-care team is there for exactly that, and asking for it is a reasonable thing to do.

Medical disclaimer: This page explains what FAMMM syndrome and an inherited CDKN2A change mean for pancreatic cancer risk, and is reviewed by a CION medical oncologist with reference to NCCN and international consensus guidance on hereditary pancreatic cancer and high-risk surveillance. It is general information and not a substitute for genetic counselling; whether testing or surveillance is right for you depends on your own family history and must be decided with your treating team. Genetic counselling and germline testing, ordering and reporting of pancreatic-protocol CT, MRI/MRCP, CA 19-9 and bloods, chemotherapy, radiation, chemoradiation and SBRT, nutrition and pancreatic enzyme (PERT) support, pain, psycho-oncology and survivorship care are delivered by CION. Endoscopic ultrasound and biopsy, ERCP and biliary or duodenal stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, peptide receptor radionuclide therapy and all pancreatic surgery are coordinated with specialist hepatobiliary, gastroenterology, endoscopy and nuclear medicine partner centres and may be billed there.